title: Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.
abstract: The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).
authors.affiliation: Division of Medicinal Safety Science, National Institute of Health Sciences, Kamiyoga, Setagaya, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Saito
authors.affiliation: Department of Medicine, University of Otago, Christchurch, New Zealand.
authors.forename: L K
authors.initials: LK
authors.lastname: Stamp
authors.affiliation: Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
authors.forename: K E
authors.initials: KE
authors.lastname: Caudle
authors.affiliation: Departments of Medicine and Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Hershfield
authors.affiliation: Department of Genetics, Stanford University Medical Center, Stanford, California, USA.
authors.forename: E M
authors.initials: EM
authors.lastname: McDonagh
authors.affiliation: ACOS for Research, Department of Veterans Affairs Medical Center, Indianapolis, Indiana, USA.|Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.|Department of Pharmacology/Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
authors.forename: J T
authors.initials: JT
authors.lastname: Callaghan
authors.affiliation: Department of Pharmacology, Research and Diagnostic Center for Emerging Infectious Diseases, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
authors.forename: W
authors.initials: W
authors.lastname: Tassaneeyakul
authors.affiliation: Laboratory for Pharmacogenetics, RIKEN, Center for Genomic Medicine, Yokohama, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Mushiroda
authors.affiliation: Institute of Data Analysis, StaGen, Tokyo, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Kamatani
authors.affiliation: Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: Goldspiel
authors.affiliation: Division of Infectious Diseases, Institute of Immunology and Infectious Disease, Murdoch University, Murdoch, Western Australia.|Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
authors.forename: E J
authors.initials: EJ
authors.lastname: Phillips
authors.affiliation: Department of Genetics, Stanford University Medical Center, Stanford, California, USA.
authors.forename: T E
authors.initials: TE
authors.lastname: Klein
authors.affiliation: Laboratory for International Alliance on Genomic Research, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.|National Center for Genome Medicine, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.|School of Chinese Medicine, China Medical University, Taichung, Taiwan.
authors.forename: M T M
authors.initials: MT
authors.lastname: Lee
mesh_terms: D000493:Allopurinol / Q000008:administration & dosage*; D054316:Biomarkers, Pharmacological; D004334:Drug Administration Schedule; D005838:Genotype; D017408:Guidelines as Topic / Q000592:standards*; D015235:HLA-B Antigens / Q000235:genetics*; D006801:Humans
chemical_list: D054316:Biomarkers, Pharmacological; D015235:HLA-B Antigens; D000493:Allopurinol